<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235608</url>
  </required_header>
  <id_info>
    <org_study_id>SESAR - RBHP 2018 JABAUDON</org_study_id>
    <nct_id>NCT04235608</nct_id>
  </id_info>
  <brief_title>SEvoflurane for Sedation in ARds</brief_title>
  <acronym>SESAR</acronym>
  <official_title>Sevoflurane for Sedation in Acute Respiratory Distress Syndrome: A Multicenter Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether a sedation with inhaled sevoflurane will decrease mortality and
      increase time off the ventilator at 28 days in patients with acute respiratory distress
      syndrome (ARDS).

      Half of the patients will receive inhaled sedation with sevoflurane and the other half will
      receive intravenous sedation with propofol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      To assess the efficacy of a sedation with inhaled sevoflurane in improving in reducing
      mortality and morbidity in patients with moderate-severe ARDS in comparison to a control
      group receiving intravenous sedation with propofol.

      PRIMAY HYPOTHESIS:

      Inhaled sedation with sevoflurane will improve a composite outcome of mortality and time off
      the ventilator at 28 days, in patients with moderate-severe ARDS.

      The trial will accrue a maximum of 700 patients. Patients will be recruited from
      participating intensive care units and randomized to the active (inhaled sevoflurane) or
      control (intravenous propofol).

      The overall strategy is to screen and enroll early, every newly intubated, acutely ill or
      postoperative, patient at each site, using clinically obtained pulse oximetry and blood
      gases.

      By providing superior awakening and extubation times, as well as lung-protective effects from
      anti-inflammatory and protective effects from epithelial injury, inhaled sevoflurane may
      hasten recovery from lung injury and improve outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 3, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Investigator-initiated, multicenter, prospective, randomized, stratified, parallel-group clinical trial with blinded outcome assessment and concealed allocation of patients with moderate-to-severe ARDS to a strategy of inhaled sedation with sevoflurane or to a strategy of current intravenous sedation practice using propofol.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>At each participating center, patients will be followed up for primary and secondary endpoints by members of the research staff who will be unaware of the trial group allocation. Information on whether the primary and secondary outcomes occur will be collected and entered into the electronic web-based case report form (eCRF) by trial or clinical trained personal (clinical research associate), blinded to the allocation group, under the supervision of the local principal investigator (PI) or designee who will also be unaware of the trial group allocation.
Finally, the independent trial statistician and the members of the data monitoring and safety committee (DMSC) will also remain blinded for the allocation during analysis. However, the observation of differences in serious adverse events between the two groups will allow, for safety reasons may the DMSC deem necessary, to unblind allocation groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days off the ventilator</measure>
    <time_frame>Day 28</time_frame>
    <description>VFD28, for ventilator-free days to taking into account death as a competing event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Day 90</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Day 28</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality rate</measure>
    <time_frame>Day 28</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Organ failure-free days to day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Organ failure is defined as present on any date when the most abnormal vital signs or clinically available lab value meets the definition of clinically significant organ failure according to SOFA scores. Patients will be followed for development of organ failures to death, hospital discharge or study day 28, whichever comes first. Each day a patient is alive and free of a given organ failure will be scored as a failure-free day. Any day that a patient is alive and free of all organ failures will represent days alive and free of all organ failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of rescue procedures used for ARDS</measure>
    <time_frame>DAY 28</time_frame>
    <description>Rescue procedures will be chosen according to the practice at clinical sites. We will record the use of the following rescue procedures through study day 28: nitric oxide, epoprostenol sodium, high frequency ventilation, use of neuromuscular blockade after 48 h from randomization, and extracorporeal membrane oxygenation (ECMO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-acquired weakness</measure>
    <time_frame>ICU Discharge until Day 28</time_frame>
    <description>Manual muscle strength testing will be attempted at study day 7, and then every 7 days thereafter, until ICU discharge or day 28 (whichever comes first). Patients will be defined as having ICU acquired weakness if their Medical Research Council (MRC) score is &lt;48 (or mean MRC &lt;4 for each muscle group tested).
o Highest level of mobility will be assessed on study days 1-7 using the ICU Mobility Scale, and then every 7 days thereafter, until ICU discharge or day 28 (whichever comes first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-acquired delirium</measure>
    <time_frame>Day 14</time_frame>
    <description>Confusion Assessment Method for the ICU (CAM-ICU) and the Intensive Care Delirium Screening Checklist will be assessed daily to death or ICU discharge. Delirium-free and coma-free days will be assessed as secondary outcomes. Delirium-free and coma-free days are defined as the number of days during which the patient is alive without delirium and not in coma from any cause. Patients who die within will be recorded as having zero days free of delirium and coma. The incorporation of delirium-free and coma-free days is a means of having a measure of normal brain function, in which being assessed as CAM-ICU negative is defined as normal. The recording of patients who die within the study period as having zero days free of delirium or coma addresses the situation in which an intervention might increase the number of delirium-free and coma-free days but cause harm and increase mortality. A composite criterion of delirium-free, coma-free, and ventilator-free days will be assessed too.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-acquired delirium</measure>
    <time_frame>Day 28</time_frame>
    <description>Confusion Assessment Method for the ICU (CAM-ICU) and the Intensive Care Delirium Screening Checklist will be assessed daily to death or ICU discharge. Delirium-free and coma-free days will be assessed as secondary outcomes. Delirium-free and coma-free days are defined as the number of days during which the patient is alive without delirium and not in coma from any cause. Patients who die within will be recorded as having zero days free of delirium and coma. The incorporation of delirium-free and coma-free days is a means of having a measure of normal brain function, in which being assessed as CAM-ICU negative is defined as normal. The recording of patients who die within the study period as having zero days free of delirium or coma addresses the situation in which an intervention might increase the number of delirium-free and coma-free days but cause harm and increase mortality. A composite criterion of delirium-free, coma-free, and ventilator-free days will be assessed too.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Day 90</time_frame>
    <description>Katz Activities of Daily Living (ADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Day 365</time_frame>
    <description>Katz Activities of Daily Living (ADL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (including utilities)</measure>
    <time_frame>Day 90</time_frame>
    <description>Short Form-36 (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (including utilities)</measure>
    <time_frame>Day 365</time_frame>
    <description>Short Form-36 (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rated health</measure>
    <time_frame>Day 90</time_frame>
    <description>Health questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rated health</measure>
    <time_frame>Day 365</time_frame>
    <description>Health questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-interference</measure>
    <time_frame>Day 90</time_frame>
    <description>Pain-interference: 1 standard item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-interference</measure>
    <time_frame>Day 365</time_frame>
    <description>Pain-interference: 1 standard item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-traumatic Stress-like Symptoms</measure>
    <time_frame>Day 90</time_frame>
    <description>Post-Traumatic Stress Symptoms (PTSS-14), Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-traumatic Stress-like Symptoms</measure>
    <time_frame>Day 365</time_frame>
    <description>Post-Traumatic Stress Symptoms (PTSS-14), Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Day 90</time_frame>
    <description>The Alzheimer's Disease 8 (AD8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Day 365</time_frame>
    <description>The Alzheimer's Disease 8 (AD8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent return to work rate</measure>
    <time_frame>Day 90</time_frame>
    <description>Subsequent return to work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subsequent return to work rate</measure>
    <time_frame>Day 365</time_frame>
    <description>Subsequent return to work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital and ED use rate</measure>
    <time_frame>Day 90</time_frame>
    <description>Hospital and ED use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital and ED use rate</measure>
    <time_frame>Day 365</time_frame>
    <description>Hospital and ED use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>location of residence</measure>
    <time_frame>Day 90</time_frame>
    <description>location of residence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>location of residence</measure>
    <time_frame>Day 365</time_frame>
    <description>location of residence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (plasma and urine) (exploratory outcome)</measure>
    <time_frame>Day 1</time_frame>
    <description>Plasma and urine samples will be collected from indwelling catheters (when available) to assemble a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane in patients with ARDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (plasma and urine) (exploratory outcome)</measure>
    <time_frame>Day 2</time_frame>
    <description>Plasma and urine samples will be collected from indwelling catheters (when available) to assemble a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane in patients with ARDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (plasma and urine) (exploratory outcome)</measure>
    <time_frame>Day 4</time_frame>
    <description>Plasma and urine samples will be collected from indwelling catheters (when available) to assemble a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane in patients with ARDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (plasma and urine) (exploratory outcome)</measure>
    <time_frame>Day 6</time_frame>
    <description>Plasma and urine samples will be collected from indwelling catheters (when available) to assemble a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane in patients with ARDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (plasma and urine) (exploratory outcome)</measure>
    <time_frame>ICU discharge Day 14</time_frame>
    <description>Plasma and urine samples will be collected from indwelling catheters (when available) to assemble a biological collection aimed at further investigating the effects of inhaled sedation with sevoflurane in patients with ARDS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (whole blood for RNA and DNA studies) (exploratory outcome)</measure>
    <time_frame>Inclusion</time_frame>
    <description>Whole blood samples will be collected for future RNA and DNA studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (whole blood for RNA and DNA studies) (exploratory outcome)</measure>
    <time_frame>Day 2</time_frame>
    <description>Whole blood samples will be collected for future RNA and DNA studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (undiluted pulmonary edema fluid) (exploratory outcome)</measure>
    <time_frame>Inclusion</time_frame>
    <description>Undiluted pulmonary edema fluid samples will be collected in some patients enrolled in selected centers (because of logistical considerations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (undiluted pulmonary edema fluid) (exploratory outcome)</measure>
    <time_frame>Day 1</time_frame>
    <description>Undiluted pulmonary edema fluid samples will be collected in some patients enrolled in selected centers (because of logistical considerations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (noninvasive sampling of the distal airspace) (exploratory outcome)</measure>
    <time_frame>Day 1</time_frame>
    <description>heat moisture exchanger and AnaConDa-S filters will be collected at 24 hours in those patients randomized to the control and intervention groups (n=50 patients from each group), respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker studies (bronchoalveolar lavage fluid) (exploratory outcome)</measure>
    <time_frame>Between Day 2 and Day 4</time_frame>
    <description>Bronchoalveolar lavage fluid samples will be collected from a total of 25 intubated patients enrolled in 5 selected centers (because of logistical considerations)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis (exploratory outcome)</measure>
    <time_frame>Hospital discharge until day 365</time_frame>
    <description>Healthcare-related costs during ICU stay and hospital stay will be assessed in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>inhaled sedation with sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled sedation with sevoflurane, as vaporized via the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous sedation with propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous sedation with propofol, as already routinely used in participating ICUs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled sedation with sevoflurane</intervention_name>
    <description>Inhaled sedation with sevoflurane using the Anesthesia Conserving Device (AnaConDa-S, Sedana Medical, Danderyd, Sweden).</description>
    <arm_group_label>inhaled sedation with sevoflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous sedation with propofol</intervention_name>
    <description>intravenous sedation with propofol, as already routinely used in participating ICUs.</description>
    <arm_group_label>intravenous sedation with propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Presence for ≤24 hours of all of the following conditions, within one week of a
             clinical insult or new or worsening respiratory symptoms:

               -  PaO2/FiO2 &lt;150 mmHg with positive end-expiratory pressure (PEEP) ≥8 cmH2O (or, if
                  arterial blood gas not available, SpO2/FiO2 that is equivalent to a PaO2/FiO2
                  &lt;150 mmHg with PEEP ≥8 cmH2O and a confirmatory SpO2/FiO2 between 1-6 hours after
                  the initial SpO2/FiO2 determination)

               -  Bilateral opacities not fully explained by effusions, lobar/lung collapse, or
                  nodules

               -  Respiratory failure not fully explained by cardiac failure or fluid overload;
                  need objective assessment (e.g., echocardiography) to exclude hydrostatic edema
                  if no risk factor present

        Exclusion Criteria:

          -  Absence of affiliation to the French Sociale security

          -  Patient under a tutelage measure or placed under judicial protection

          -  Continuous sedation with inhaled sevoflurane at enrollment

          -  Known pregnancy

          -  Currently receiving ECMO therapy

          -  Chronic respiratory failure defined as PaCO2 &gt;60 mmHg in the outpatient setting

          -  Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for
             CPAP/BIPAP used solely for sleep-disordered breathing

          -  Body mass index &gt;40 kg/m2

          -  Chronic liver disease defined as a Child-Pugh score of 12-15

          -  Expected duration of mechanical ventilation &lt;48 hours

          -  Moribund patient, i.e. not expected to survive 24 hours despite intensive care

          -  Burns &gt;70% total body surface

          -  Previous hypersensitivity or anaphylactic reaction to sevoflurane or cisatracurium

          -  Medical history of malignant hyperthermia

          -  Long QT syndrome at risk of arrhythmic events

          -  Medical history of liver disease attributed to previous exposure to a halogenated
             agent (including sevoflurane)

          -  Known hypersensitivity to propofol or any of its components

          -  Known allergy to eggs, egg products, soybeans, and soy products

          -  Suspected or proven intracranial hypertension

          -  Tidal volume of 6 mL/kg predicted body weight (PBW) below 200 mL (as recommended by
             the manufacturer for the use of the AnaConDa-S (Sedana Medical, Danderyd, Sweden)

          -  Enrollment in another interventional ARDS trial with direct impact on sedation and
             mechanical ventilation

          -  Endotracheal ventilation for greater than 120 hours (5 days)

          -  Persistent bronchopleural fistula despite chest tube drainage

          -  PaO2/FiO2 (if available) &gt;200 mmHg after meeting inclusion criteria and before
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu Jabaudon</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raïko Blondonnet</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Michel Constantin</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP - La Pitié Salpêtrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karim Asehnoune</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samir Jaber</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Montpellier - Saint-Eloi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elie Azoulay</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP - Saint-Louis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole Ichai</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lionel Velly</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHM - La Timone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Yves Lefrant</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nîmes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sigismond Lasocki</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre Quenot</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Seguin</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>François Legay</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Brieuc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnaud W. Thille</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Poitiers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Lautrette</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean-Perrin Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Pottecher</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Garnier</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP - Saint-Antoine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Vinsonneau</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Béthune</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-Marie Bertrand</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Cannes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Guaguère</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Douai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillaume Grillet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Bretagne Sud - Lorient</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehran Monchi</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Melun-Sénart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joël Cousson</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Maizel</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erwan L'Her</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Nowobilski</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Jung</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Montpellier - Lapeyronie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Dahyot-Fizelier</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Poitiers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Amathieu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Diaconesses - La Croix Simon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline Varillon</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Dunkerque</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arthur Durand,</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Gainnier</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHM - La Timone</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>+33 4 73 754963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Maizel</last_name>
      <email>maizel.julien@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigismond Lasocki</last_name>
      <email>silasocki@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cavale Blanche Hospital - University Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwan L'Her</last_name>
      <email>erwan.lher@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Béthune</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Vinsonneau,</last_name>
      <email>cvinsonneau@ch-bethune.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie Bertrand</last_name>
      <email>pm.bertrand@ch-cannes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital,</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Jabaudon</last_name>
      <phone>0473278080</phone>
      <email>mjabaudon@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Raiko Blondonnet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jean Perrin Comprehensive Cancer Center</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Lautrette,</last_name>
      <email>alexandre.lautrette@cjp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Quenot</last_name>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Nowobilski</last_name>
      <email>nicolas.nowobilski@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Douai</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Guaguère</last_name>
      <email>anne.guaguere@ch-douai.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Varillon,</last_name>
      <email>caroline.varillon@ch-dunkerque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salengro Hospital - University Hospital</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur Durand</last_name>
      <email>arthur.durand@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Timone Hospital - Assistance Publique-Hôpitaux</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Velly</last_name>
      <email>lionel.velly@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Timone Hospital - Assistance Publique-Hôpitaux</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Gainnier</last_name>
    </contact>
    <contact_backup>
      <email>marc.gainnier@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehran Monchi</last_name>
      <phone>0164716000</phone>
      <email>mn.monchi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lapeyronie Hospital - University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Jung</last_name>
      <email>b-jung@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Eloi Hospital - University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Jaber</last_name>
      <email>s-jaber@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Hospital - University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Asehnoune</last_name>
      <email>karim.asehnoune@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pasteur 2 Hospital - University Hospital</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Ichai</last_name>
      <email>ichai@unice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carémeaux Hospital - University Hospita</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves Lefrant,</last_name>
      <email>jean.yves.lefrant@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diaconesses - La Croix Simon Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Amathieu</last_name>
      <email>amathieu@univ-paris13.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital, - Assistance Publique-Hôpitaux</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel Constantin</last_name>
      <email>jean-michel.constantin@psl.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Antoine University Hospital - Assistance Publique-Hôpitaux</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Garnier</last_name>
      <email>marc.garnier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Louis University Hospital - Assistance Publique-Hôpitaux</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Azoulay</last_name>
      <email>elie.azoulay@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud W. Thille</last_name>
      <email>aw.thille@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Dahyot-Fizelier</last_name>
      <email>Claire.DAHYOT-FIZELIER@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël Cousson</last_name>
      <email>jcousson@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Seguin</last_name>
      <email>philippe.seguin@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautepierre Hospital, University Hospitals</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Pottecher</last_name>
      <email>julien.pottecher@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>Sedation</keyword>
  <keyword>Inhaled sevoflurane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

